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To answer Roscoe, the key issue is the quality of the data being collected rather than the 
numbers entailed.1 2 Although the Quality and Outcomes Framework database comprises a 
much larger sample, smoking status is not assessed using a standardised question and the 
exact timing of the assessments is unclear. The large sample included in that database is also 
unlikely to be representative of the general population. For example, as pointed out by 
Roscoe,1 smokers are more likely to have had contact with their GP than non-smokers. 
 
As a point of information, the total sample size for our study in 2013 was 22 167, rather than 
the 1800 cited by Roscoe. The figure of 1800 refers to the approximate monthly sample size. 
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